|Tuesday, 20 September 2016, 07:30 HKT/SGT|
Paris, France and Cambridge, Massachusetts, USA, Sept 20, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of EUR 2M for Innovation (pret a taux zero pour l'Innovation - PTZI).
The interest-free loan, repayable from September 2019, aims to support the development of Nanobiotix's lead product, NBTXR3, which is currently under registration trial (Phase II/III) with Soft Tissue Sarcoma. Nanobiotix has recently filed for a CE Mark for the product.
A nanomedicine product in registration phase
NBTXR3 is a first-in-class radio-enhancer based on the NanoXray technology, designed for direct injection into cancerous tumors. The product is engineered to increase the dose and efficacy of radiotherapy without increasing toxicity or causing damage to surrounding healthy tissues.
NBTXR3 is currently in clinical development in six indications: Soft Tissue Sarcoma, Head and Neck cancers, Prostate, Liver cancers (primary and metastases) and rectal (via PharmaEngine, partner for the Asia Pacific area).
Philippe Mauberna, CFO of Nanobiotix, commented: "Bpifrance has shown Nanobiotix a continual high level of support since our inception for which we are very pleased. This interest-free loan will contribute to financing the last steps of the NBTXR3 registration study in Soft Tissue Sarcoma. This is an exciting period for the Company."
Bpifrance, a historic partner of the Company
Bpifrance (ex OSEO), has supported Nanobiotix's dynamic development for over 12 years. This support has taken a number of forms such as repayable grants or inclusion in Strategic Industrial Innovation (ISI) programs, such as the "NICE project", a collaborative project dedicated to liver cancers and managed by Bpifrance.
Eric Tossah, Bpifrance, commented: "The Bpifrance team is delighted to put this new loan together for Nanobiotix which demonstrates our deep support and confidence in this innovative French technology. Nanobiotix is rapidly growing with an international and renowned management team. They launched an affiliate in the Boston area two years ago, and have welcomed a number of North American life sciences specialist investors."
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck cancer, prostate cancer, rectal cancer (PharmaEngine) and liver cancers (HCC and liver metastases). The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
For more information, please visit www.nanobiotix.com
About Bpifrance: www.bpifrance.fr
Bpifrance, a subsidiary of the French state and the "Caisse des Depots" and the entrepreneurs' trusted partner, finances businesses from the seed phase to IPO, through loans, guarantees and equity investments.
Bpifrance also provides operational services and strong support for innovation, export, and external growth in partnership with Business France and Coface. Bpifrance offers to businesses a large range of financing opportunities at each key step of their development, including offers adapted to regional specificities. With its 45 regional offices (90% of decisions are made locally) Bpifrance represents a strategic tool for economic competitiveness dedicated to entrepreneurs.
Bpifrance acts as a back-up for initiatives driven by the French State and the Regions to tackle 3 goals:
- Contributing to SME's growth
- Preparing tomorrow's competitiveness
- Contributing to the development of a positive entrepreneur ecosystem.
With Bpifrance, businesses benefit from a powerful, efficient and close representative, to answer all their needs in terms of financing, innovation and investment.
More info: www.bpifrance.fr - Follow us: @bpifrance
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
France - NewCap
+33 (0)6 88 20 35 59
EU Outside France - Instinctif Partners
Melanie Toyne Sewell
+44 (0) 207 457 2020
United States - The Ruth Group
Kirsten Thomas / Chris Hippolyte
+1 508-280-6592 / +1 646-536-7023
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorite des Marches Financiers) under number D.16-0732 on July 22, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NANOBIOTIX via Globenewswire
Sept 20, 2016 07:30 HKT/SGT
Topic: Press release summary
From the Asia Corporate News Network
Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|Apr 18, 2018 09:00 HKT/SGT|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway|
|Apr 11, 2018 09:00 HKT/SGT|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab|
|Mar 30, 2018 22:10 HKT/SGT|
Nanobiotix 2017 Annual Results|
|Jan 22, 2018 15:00 HKT/SGT|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting|
|Jan 11, 2018 15:00 HKT/SGT|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers|
|Dec 26, 2017 15:50 HKT/SGT|
Nanobiotix: 2017 review and 2018 expected milestones|
|Dec 26, 2017 15:15 HKT/SGT|
FDA approves Nanobiotix's first Immuno-Oncology trial|
|Nov 13, 2017 15:00 HKT/SGT|
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting|
|Nov 10, 2017 08:30 HKT/SGT|
Nanobiotix provides update on the global development of its lead product NBTXR3|
|Oct 23, 2017 14:00 HKT/SGT|
Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma|
|More news >>|